Depression-related cognitive impairment: Possibilities for its pharmacological treatment
A.J. Mitchell
Bok Engelsk 1996
| Utgitt | 1996
|
|---|---|
| Omfang | Side 79- 87
|
| Opplysninger | Depression-related cognitive impairment (DRCI) is a condition which despite its initial treatment response, shows a progressive deterioration. Noconsistent therapeutic strategies have been proposed to combat this condition. This may be due to a reluctance to treat the cognitively impaired, a failure to recognise the deleterious prognosis or a poor understanding of the likely pathogenesis. Increasing evidence implicates the hypothalamo-pituitary-adrenal (HPA) axis as a key neurobiological determinant of the presentationand course of depression-induced cognitive decline. By utilising agents which control central glucocorticoid hyperactivity over a sustained period, whilst avoiding those agents which may compromise cognitive abilities, there exists a pharmacological strategy which may minimise the morbidity of cognitiveimpairment related to depressive illness.
|
| Emner |
